A Phase 1 interventional study of Vonoprazan in Gastroesophageal Reflux, sponsored by Phathom Pharmaceuticals, Inc.. Completed at 10 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Phathom Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 1, and was the 7th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:
Phathom Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
Tanta University · Sites in Egypt
Ages 17–60
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 20–75
By country, each count listing its studies:
vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 118 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Phathom Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 11 (100%) have results posted.
Phathom Pharmaceuticals, Inc. has 4 studies filed under Gastroesophageal Reflux — fewer than ten, so there is no comparison to draw.
2 of the studies testing vonoprazan in Gastroesophageal Reflux that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07752407Phase 3Phathom Pharmaceuticals, Inc.A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | 2027-10-20 |
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the pharmacokinetic profile of vonoprazan in adolescent participants with symptomatic gastroesophageal reflux disease (GERD).
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive vonoprazan 10 mg once daily for 14 days.
Drug: Vonoprazan
Participants will receive vonoprazan 20 mg once daily for 14 days.
Drug: Vonoprazan
Oral Tablet
Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan
Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Apparent Oral Clearance (CL/F) of Vonoprazan
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Apparent Central Volume of Distribution (Vc/F) of Vonoprazan
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
Time frame: Blood samples were collected predose, once between 0.5 and 2 hours, and once between 2.5 and 4 hours post-dose on Days 7 and 14
Number of Participants Experiencing Adverse Events (AEs)
AE: any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug. Treatment-emergent adverse event (TEAE): any AE that occurred after the first dose of study drug or at baseline that worsens in either intensity or frequency after the first dose of study drug. Serious AE: any AE for which the following occurred: death, was life threatening, hopsitalization or prolongation of hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or the AE was deemed an important medical event. Related AE: any AE that follows a reasonable temporal sequence from administration of study drug, or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug may also be responsible. Clinically significant changes from baseline in laboratory test values, (hematology, serum chemistry and urinalysis), electrocardiograms and vital signs were reported as AEs.
Time frame: Up to Day 28
A total of 24 participants were enrolled into this study in the United States between May 2022 and June 2023.
| Milestone | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 11 |
| Not completed | 0 | 1 |
| Withdrew: Miscellaneous | 0 | 1 |
Plasma pharmacokinetic (PK) parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
| ng/mL | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Maximum Observed Drug Concentration at Steady State (Cmax-ss) of Vonoprazan | 13.4 (6.57 to 25.6) | 26.7 (13.1 to 49.1) |
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
| h*ng/mL | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Area Under the Plasma Concentration-time Curve During the Dosing Interval τ (AUCτ) of Vonoprazan | 94.6 (56.0 to 165) | 208 (95.6 to 381) |
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
| L/h | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Apparent Oral Clearance (CL/F) of Vonoprazan | 124 (60.5 to 179) | 117 (52.5 to 209) |
PK parameters were estimated using a non-linear mixed effects model and were determined from the concentration-time data for all evaluable participants. Actual sampling times, rather than scheduled or nominal sampling times, were used in all computations using sampling time.
| liters | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Apparent Central Volume of Distribution (Vc/F) of Vonoprazan | 686 (314 to 1280) | 704 (311 to 1110) |
AE: any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug. Treatment-emergent adverse event (TEAE): any AE that occurred after the first dose of study drug or at baseline that worsens in either intensity or frequency after the first dose of study drug. Serious AE: any AE for which the following occurred: death, was life threatening, hopsitalization or prolongation of hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or the AE was deemed an important medical event. Related AE: any AE that follows a reasonable temporal sequence from administration of study drug, or for which possible involvement of the drug cannot be ruled out, although factors other than the study drug may also be responsible. Clinically significant changes from baseline in laboratory test values, (hematology, serum chemistry and urinalysis), electrocardiograms and vital signs were reported as AEs.
| Participants | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| Any TEAEs | 4 | 1 |
| Any Serious TEAEs | 0 | 0 |
| Any Study Drug-related TEAEs | 0 | 0 |
| Any Serious Study Drug-related TEAEs | 0 | 0 |
| Any TEAE Leading to Treatment Discontinuation | 0 | 0 |
| Any TEAE Leading to Study Discontinuation | 0 | 0 |
| Any AEs Leading to Death | 0 | 0 |
Collected over Up to Day 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vonoprazan 10 mg QD | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| Vonoprazan 20 mg QD | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Event | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD |
|---|---|---|
| CellulitisInfections and infestations | 1/12 | 0/12 |
| Enterocolitis infectiousInfections and infestations | 0/12 | 1/12 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/12 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 0/12 |
| MigraineNervous system disorders | 1/12 | 0/12 |
| AnxietyPsychiatric disorders | 1/12 | 0/12 |
Safety Set: inclusive of all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD | Total |
|---|---|---|---|
| Mean | 14.3 ± 1.78 | 15.2 ± 1.75 | 14.8 ± 1.78 |
| Sex: Female, Male(Participants) | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD | Total |
|---|---|---|---|
| Female | 6 | 7 | 13 |
| Male | 6 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 2 | 6 |
| Not Hispanic or Latino | 6 | 10 | 16 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Vonoprazan 10 mg QD | Vonoprazan 20 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 8 |
| White | 9 | 7 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2022 to primary completion in May 2023, 12 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Gastroesophageal Reflux, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 12 months is above that.
Counting every sponsor, half of 34 studies reached it within 4 months; a quarter within 2 and three quarters within 10.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan
Phathom Pharmaceuticals, Inc.